USE OF TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICINE FOR TREATMENT OF NON-HODGKIN'S LYMPHOMAS

摘要

PROBLEM TO BE SOLVED: To manufacture a medicament for treating cancers, particularly cancers expressing CD20.SOLUTION: Type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC), in combination with one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine, is used.SELECTED DRAWING: Figure 4